Pancreatic Cancer Research

ResearcherZhejiang Chinese Medical UniversityActive in the last 2 years

Nan Niu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2360-2384; OpenAlex author ID A5088277227. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2020: 3 papers · 2021: 1 paper · 2022: 5 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 13

  1. Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer. Co-author DOI 10.1186/s40364-024-00721-7↗
  2. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Co-author DOI 10.1126/sciadv.adk1827↗
  3. Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. Co-author DOI 10.1186/s13045-024-01576-z↗
  4. CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2023.06.037↗
  5. Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model. Co-author DOI 10.1016/j.canlet.2022.215722↗
  6. Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. Co-author DOI 10.1053/j.gastro.2022.06.027↗
  7. CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. Co-author DOI 10.1084/jem.20211631↗
  8. Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spectrometry. Co-author DOI 10.1186/s13045-022-01373-6↗
  9. Clinical outcome comparison of laparoscopic radical antegrade modular pancreatosplenectomy vs. laparoscopic distal pancreatosplenectomy for left-sided pancreat… Co-author DOI 10.3389/fsurg.2022.981591↗
  10. Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells. Co-author DOI 10.20892/j.issn.2095-3941.2020.0273↗
  11. Laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic outcomes and long-term survival. Co-author DOI 10.1007/s00464-019-06968-8↗
  12. Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. Co-author DOI 10.1016/j.cdtm.2020.01.002↗
  13. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1025↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lei Zheng · 10 shared papers, 2020–2025 · strength 1.32
  2. Keyu Li · 8 shared papers, 2020–2025 · strength 1.10
  3. Brian T. Herbst · 6 shared papers, 2021–2025 · strength 0.87
  4. Arsen Osipov · 5 shared papers, 2021–2024 · strength 0.66
  5. Junke Wang · 4 shared papers, 2022–2024 · strength 0.53
  6. Jun-Ke Wang · 3 shared papers, 2022–2025 · strength 0.48
  7. Yao Xu · 4 shared papers, 2021–2023 · strength 0.48
  8. Yiping Mou · 3 shared papers, 2020–2025 · strength 0.47
  9. Noah S Rozich · 3 shared papers, 2022–2024 · strength 0.40
  10. Stephen T. Muth · 3 shared papers, 2022 · strength 0.40
  11. Alex B. Blair · 3 shared papers, 2021–2024 · strength 0.38
  12. Mengni He · 2 shared papers, 2024–2025 · strength 0.37
  13. Pan Li · 3 shared papers, 2022–2023 · strength 0.37
  14. Jianxin Wang · 3 shared papers, 2020–2022 · strength 0.35
  15. Daniel A. Laheru · 3 shared papers, 2020–2024 · strength 0.35
  16. Tengyi Zhang · 2 shared papers, 2022–2024 · strength 0.31
  17. Noelle R. Jurcak · 2 shared papers, 2023–2024 · strength 0.29
  18. Chunhui Yuan · 2 shared papers, 2020–2024 · strength 0.28
  19. Kenji Fujiwara · 2 shared papers, 2022 · strength 0.27
  20. Jin Peng He · 2 shared papers, 2022–2024 · strength 0.27
  21. Amol Kumar Narang · 2 shared papers, 2022–2024 · strength 0.27
  22. Yucheng Zhou · 2 shared papers, 2020–2022 · strength 0.26
  23. Weiwei Jin · 2 shared papers, 2020–2022 · strength 0.26
  24. Sophia Y. Chen · 2 shared papers, 2022–2023 · strength 0.25
  25. Robert A. Anders · 2 shared papers, 2020–2024 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.